1Johnston SRD, Harbeck N, Hegg R, et al; monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987-3998. https://doi.org/10.1200/JCO.20.02514
2Vasconcelos I, Hussainzada A, Berger S, et al. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival. Breast. 2016;29:181-185. https://doi.org/10.1016/j.breast.2016.07.016
3Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533-1546. https://doi.org/10.1093/annonc/mdv221
4Nielsen TO, Leung SC, Rimm DL, et al. Assessment of Ki67 in breast cancer: updated recommendations form the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2020;113(7):808-819. https://doi.org/10.1093/jnci/djaa201
5Fasching PA, Gass P, Häberle L, et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast Cancer Res Treat. 2019;175(3):617-625. http://dx.doi.org/10.1007/s10549-019-05198-9
6Gluz O, Nitz UA, Christgen M, et al. West German study group phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016;34(20):2341-2349. https://doi.org/10.1200/JCO.2015.63.5383
7Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology. 2017;49(2):166-171. https://doi.org/10.1016/j.pathol.2016.11.006